DEPO-TESTOSTERONE INJ 100MG/ML SOLUTION

Страна: Канада

Език: английски

Източник: Health Canada

Купи го сега

Активна съставка:

TESTOSTERONE CYPIONATE

Предлага се от:

PFIZER CANADA ULC

АТС код:

G03BA03

INN (Международно Name):

TESTOSTERONE

дозиране:

100MG

Лекарствена форма:

SOLUTION

Композиция:

TESTOSTERONE CYPIONATE 100MG

Начин на приложение:

INTRAMUSCULAR

Броя в опаковка:

10ML

Вид предписание :

Schedule G (CDSA IV)

Терапевтична област:

ANDROGENS

Каталог на резюме:

Active ingredient group (AIG) number: 0106401001; AHFS:

Статус Оторизация:

APPROVED

Дата Оторизация:

2001-06-04

Данни за продукта

                                _ _
_DEPO-TESTOSTERONE Product Monograph _
_ _
_Page 1 of 20_
PRODUCT MONOGRAPH
DEPO-TESTOSTERONE
testosterone cypionate injection
100 mg/mL sterile solution
USP
Androgens
Pfizer Canada Inc.
17, 300 Trans-Canada Highway
Kirkland, Quebec H9J 2M5
Date of Revision:
July 12, 2018
Submission Control No: 217239
©
Pfizer Canada Inc., 2018
_ _
_DEPO-TESTOSTERONE Product Monograph _
_Page 2 of 20 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................8
DRUG INTERACTIONS
....................................................................................................9
DOSAGE AND ADMINISTRATION
..............................................................................10
OVERDOSAGE
................................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
............................................................12
STORAGE AND STABILITY
..........................................................................................13
SPECIAL HANDLING INSTRUCTIONS
.......................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................14
PART II: SCIENTIFIC INFORMATION
...............................................................................15
PHARMACEUTICAL INFO
                                
                                Прочетете целия документ
                                
                            

Документи на други езици

Данни за продукта Данни за продукта френски 12-07-2018

Сигнали за търсене, свързани с този продукт

Преглед на историята на документите